CA3196725A1 - Methods for the detection and treatment of ovarian cancer - Google Patents

Methods for the detection and treatment of ovarian cancer

Info

Publication number
CA3196725A1
CA3196725A1 CA3196725A CA3196725A CA3196725A1 CA 3196725 A1 CA3196725 A1 CA 3196725A1 CA 3196725 A CA3196725 A CA 3196725A CA 3196725 A CA3196725 A CA 3196725A CA 3196725 A1 CA3196725 A1 CA 3196725A1
Authority
CA
Canada
Prior art keywords
ovarian cancer
recited
das
subject
n3ap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196725A
Other languages
English (en)
French (fr)
Inventor
Johannes FAHRMANN
Samir Hanash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA3196725A1 publication Critical patent/CA3196725A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA3196725A 2020-10-29 2021-10-27 Methods for the detection and treatment of ovarian cancer Pending CA3196725A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063107160P 2020-10-29 2020-10-29
US63/107,160 2020-10-29
PCT/US2021/056852 WO2022093960A1 (en) 2020-10-29 2021-10-27 Methods for the detection and treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
CA3196725A1 true CA3196725A1 (en) 2022-05-05

Family

ID=81383153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196725A Pending CA3196725A1 (en) 2020-10-29 2021-10-27 Methods for the detection and treatment of ovarian cancer

Country Status (7)

Country Link
US (1) US20240044902A1 (enExample)
EP (1) EP4237090B1 (enExample)
JP (1) JP2023548110A (enExample)
KR (1) KR20230113742A (enExample)
CN (1) CN116490776A (enExample)
CA (1) CA3196725A1 (enExample)
WO (1) WO2022093960A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020427A2 (en) * 2022-07-21 2024-01-25 Board Of Regents, The University Of Texas System Methods for the detection and treatment of ovarian cancer
KR20250017689A (ko) 2023-07-27 2025-02-04 가톨릭대학교 산학협력단 난소암 발병 위험률 예측 방법 및 분석장치

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1610127B1 (en) * 2003-03-11 2012-04-25 CRC Inc. N1,n12-diacetylspermine as tumor marker
CA2535805A1 (en) * 2003-08-15 2005-02-24 University Of Pittsburgh Of The Commnonwealth System Of Higher Education Multifactorial assay for cancer detection
MX2009000452A (es) * 2006-07-14 2011-11-07 Mannkind Corp Metodos para producir, mejorar y sostener respuestas inmunes contra epitopos restringidos mhc clase i para propositos profilacticos o terapeuticos.
CN101855553B (zh) * 2007-06-29 2014-06-11 韩国安国药品株式会社 卵巢癌的预测标记
US9733256B2 (en) * 2012-02-23 2017-08-15 Keio University Combined anticancer drug sensitivity-determining marker
WO2013188391A2 (en) * 2012-06-11 2013-12-19 Georgia Regents University Biomarkers for ovarian cancer
GB201316347D0 (en) * 2013-09-13 2013-10-30 Cancer Rec Tech Ltd Biological fluid filtration assembly
US20160282351A1 (en) * 2013-10-28 2016-09-29 Salivatech Co., Ltd. Salivary biomarkers for cancers, methods and devices for assaying the same, and methods for determining salivary biomarkers for cancers
US10377783B2 (en) * 2015-06-12 2019-08-13 Brock University Methods and compounds for enhancing contrast in magnetic resonance imaging (MRI)
TW201800408A (zh) * 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
FI3478286T3 (fi) * 2016-06-29 2024-03-14 Tesaro Inc Menetelmiä munasarjasyövän hoitamiseksi
KR102630885B1 (ko) * 2017-02-09 2024-01-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료 방법
WO2019178216A1 (en) * 2018-03-13 2019-09-19 Baylor Research Institute Methods and compositions for treating, diagnosing, and prognosing ovarian cancer
JP7272627B2 (ja) * 2019-01-24 2023-05-12 公立大学法人和歌山県立医科大学 卵巣腫瘍の評価用バイオマーカー
CN109870579B (zh) * 2019-02-03 2022-02-11 辽宁迈迪生物科技股份有限公司 单克隆抗体保护液及制备方法和应用、应用单克隆抗体保护液的试剂与免疫组化试剂盒

Also Published As

Publication number Publication date
WO2022093960A1 (en) 2022-05-05
JP2023548110A (ja) 2023-11-15
KR20230113742A (ko) 2023-08-01
EP4237090A1 (en) 2023-09-06
EP4237090A4 (en) 2024-09-25
EP4237090B1 (en) 2026-02-18
US20240044902A1 (en) 2024-02-08
CN116490776A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
Ng et al. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions
CN108957006B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
EP2362942B1 (en) Biomarkers
US20240159753A1 (en) Methods for the detection and treatment of lung cancer
AU2016214140B2 (en) Biomarkers for pancreatic cancer
JP2011523049A (ja) 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー
JP2011515666A (ja) トリプルネガティブ乳がんに関連するｄｎａ修復タンパク質およびその使用法
JP2013532830A (ja) 前立腺癌に関するバイオマーカー及びそれを使用する方法
EP3523658A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US10480034B2 (en) Cancer biomarker and diagnostic
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
WO2024107923A1 (en) Methods for the detection and treatment of lung cancer
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
US20160047000A1 (en) Methods and systems for treatment of ovarian cancer
WO2024020427A2 (en) Methods for the detection and treatment of ovarian cancer
CN111763736B (zh) 用于诊断甲状腺乳头状癌淋巴结转移的液体活检试剂盒
US20250116676A1 (en) Phosphopeptide/phosphoprotein signature predicting basal-like breast cancer recurrence
Hajam et al. Cancer proteomics: An overview
HK40090190A (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
Narain Identification and Clinical Validation of Novel Prostate Cancer Biomarkers Filamin A (flna), Filamin B (flnb), and Keratin 19 (krt19) Using Patient-Derived Omics and Bayesian Artificial Intelligence
HK40026777B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241018

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250722

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250722

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250722

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250729

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250926

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250926

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251031

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251031

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251101

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251215